Investor's Business Daily on MSN
Hims Stock Catapults 126% As Obesity-Drug Wars Wage On Amid FDA Scrutiny
Hims stock is near a buy point of 60.55 in a cup-with-handle base. The IBD 50 growth stock has gained 126% year-to-date.
Zacks Investment Research on MSN
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Hims & Hers Health, Inc. (HIMS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want ...
Detailed price information for T Rowe Price Group (TROW-Q) from The Globe and Mail including charting and trades.
Tracey Ryniec is the Value Stock Strategist for Zacks.com. She is also the Editor of the Insider Trader and Value Investor services. You can follow her on twitter at @TraceyRyniec and she also hosts ...
While DTC telehealth companies remove barriers to care for patients, questions remain regarding patient safety and proper education of these products.
The award went to Mary Brunkow, Fred Ramsdell, and Shimon Sakaguchi for their discoveries around what’s known as peripheral ...
U.S. stock indexes finished mixed Friday as the rose 0.51%. Meanwhile, the was flat, and the dropped 0.28%.
Hims & Hers is promoting Chief Commercial Officer Mike Chi to operating chief. Chi will succeed Nader Kabbani as chief operating officer on Nov. 2, the digital healthcare company said. Kabbani plans ...
Brands like Hims & Hers and Planet Fitness are known for offering wellness products to customers, but seeing how they treat ...
Today, Benzinga 's options scanner spotted 32 uncommon options trades for Hims & Hers Health. This isn't normal. The overall ...
Amazon started with a simple concept of selling books online and built on that early success by expanding to other products.
U.S. pharmaceutical company Bristol-Myers Squibb will cut prices to eligible U.S. patients for blood clot treatment Eliquis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results